The abstract is read at the publisher; the summary is JClub's.
Real-world evidence shows RSV prevention products achieve high effectiveness across infants and older adults, including linked reductions in cardiovascular events in older adults.
- Why it matters: High costs limit implementation mainly to higher-income settings, and uptake differences mean availability alone may not translate into population-level impact.
- What they did: This Review synthesizes approved RSV preventive products—maternal vaccines, infant monoclonal antibodies, and vaccines for older adults and high-risk adults—alongside real-world effectiveness and uptake evidence.
- The result: It highlights that achieving impact depends on integrating products into accessible routine care, trusted-provider recommendations, and context-sensitive delivery strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.